Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Still’s disease (AOSD). https://t.co/3FikFiGgxM

Antinuclear Antibodies (ANA) https://t.co/xERp8kev1T https://t.co/e3psPC7HIl

• Antinuclear Antibodies (ANA) | RheumNow

NPs and PAs: Opportunities Outside of the Exam Room Ben Smith, PA-C, Thomasville, GA, discusses scholarly and leadership opportunities for nurse practitioners and physician assistants, as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/Vzx6B1z2xJ

Lancet review of skin cancer risk w/ inflammatory arthritis - both melanoma and Non-melanoma skin cancers are increased in RA & inflammation. Also Package inserts for TNFi say all TNFi Rx pts should have complete skin exams "periodically". Skin cancer screening advised. https://t.co/XddFDe0xh8

“Absence of proof of efficacy does not equal proof of absence of efficacy” - Arthur Kavanaugh, MD

Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & 120 Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s, higher SDAI & CDAI. https://t.co/vJJRflJ23x

Austrian 1K Paracelsus cohort study; from 9,665, 296 (3.1%) had RA. CKD prevalence was higher in RA vs controls (11.8% vs. 6.7%, p<0.001). Albuminuria was dominant renal dz in RA (6.8% vs 4.2%, p=0.027), but missed signif after adjustments (OR 1.43; 0.96–2.13) https://t.co/9DnErwT4rX

Evaluation of Rheumatic Complaints https://t.co/cdizOgFqYf https://t.co/YHLAllxpO4

• Evaluation of Rheumatic Complaints | RheumNow

FDA has approved nerandomilast (Jascayd) for the treatment of progressive pulmonary fibrosis (PPF) in adults, based on the results of the phase 3 FIBRONEER trial. Nerandomilast is PDE4 inhibitor,, in Oct 2026 it was approved for use in diopathic pulmonary fibrosis (IPF) https://t.co/WVrGj7q7hB

2025 Adult Rheumatology Fellowship Match is Strong (Again) The ACR announced today that 2025 Medicine and Pediatric Specialties Match results show rheumatology fellowship positions continuing to fill at high rates. The Match uses a computerized process to pair applicant and https://t.co/ynP46pEKCa

ACR: New Data Highlights Urgent Need to Address Arthritis Burden New findings from national U.S. surveys reveal the profound impact of arthritis on millions of adults, especially those facing social and economic challenges. These data will be featured in an upcoming issue of https://t.co/3LlNQ3tx90

Role of the Nurse in the Care and Management of Rheumatic Diseases - EULAR Review In 2023, a EULAR subcommittee evaluated the roles of nurses and Advanced Practice Nurses (APNs) in arthritis care per EULAR guidelines. Initially proposed in 2012 and revised in 2018, the scope of https://t.co/w1IOQxcACR